Research programme: small molecule cancer therapies - FORMA/TGen Drug Development
Latest Information Update: 19 Oct 2022
At a glance
- Originator FORMA Therapeutics; TGen Drug Development
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 18 Jun 2012 Early research in Cancer in USA (unspecified route)